汉宇集团 reported revenue of ¥0.57B for the period ended 2026-06-30, +0.4% year on year. Net income was ¥0.09B, a 15.5% net margin on a 32.7% gross margin. The largest revenue line is 排水及循环泵 at 71% of the total. Free cash flow for the period was ¥0.05B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.57B | +0.4% |
| Gross profit | ¥0.19B | — |
| Operating income | ¥0.11B | — |
| Net income | ¥0.09B | -24.0% |
| Gross margin | 32.7% | Net margin 15.5% |
| Revenue Q/Q | +26.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 排水及循环泵 | ¥0.41B | 71.4% |
| 其他主营业务 | ¥0.07B | 12.0% |
| 冷凝泵 | ¥0.04B | 7.6% |
| 洗涤泵 | ¥0.03B | 5.9% |
| 其他(补充) | ¥0.02B | 3.2% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.39B | 67.3% |
| R&D | ¥0.02B | 3.2% |
| SG&A | ¥0.04B | 7.2% |
| Tax & other | ¥0.02B | 2.8% |
| Item | Amount |
|---|---|
| Total assets | ¥2.61B |
| Total liabilities | ¥0.37B |
| Shareholders' equity | ¥2.24B |
| Equity / assets | 85.8% |
| Operating cash flow | ¥0.06B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.05B |
| Cash conversion (OCF / net income) | 141% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
博济医药 ・ 科隆股份 ・ 九强生物 ・ 凯发电气 ・ 道氏技术 ・ 正业科技 ・ 金盾股份 ・ 迦南科技 ・ 中光防雷 ・ 伊之密 ・ 苏试试验 ・ 南华仪器
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies